We have reported a tumor-rejection antigen, SART1 259 , possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1 259 antigen in brain tumors, to explore for a potential molecule for use in specific imm
The influence of CD95L expression on tumor rejection in mice
✍ Scribed by Frederik H. Igney; Christian K. Behrens; Peter H. Krammer
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 362 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
We investigated in breast cancers the expression of the SART-1 gene encoding tumor rejection antigens. SART-1 mRNA was expressed in all of the samples tested. The SART-1 800 antigen was detectable in 20 of 50 (40%) breast cancer tissues and all breast cancer cell lines tested, but not in normal brea
## Abstract The role of glutathione S‐transferase π (GSTπ) in tumor development has been previously suggested; however the exact function of this enzyme in carcinogenesis remains unclear. GSTπ has been identified as a modulator of cell signaling by interacting with and inhibiting c‐Jun N‐terminal k
The cell surface glycoprotein MUC18MCAM/CD146 was originally defined as a marker of melanoma progression and has been suspected to be directly linked to the metastatic process of this malignancy. In order to address this question, 2 MCAM negative human melanoma cell lines, SK-2 and XP44RO(Mel), were